Apollomics (APLM) Current Deferred Tax Assets (2022 - 2024)
Apollomics (APLM) posted quarterly Current Deferred Tax Assets of $41.2 million for Q2 2023, down 5.05% quarter-over-quarter from $43.4 million in Q4 2022.
Apollomics (APLM) Current Deferred Tax Assets (2022 - 2024) Analysis & Trends
Apollomics (APLM) has reported Current Deferred Tax Assets for 2 consecutive years, with $41.2 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Current Deferred Tax Assets changed N/A year-over-year to $41.2 million; the TTM figure through Jun 2023 stood at $41.2 million (changed N/A YoY), while the FY2024 annual figure was $2.9 million, changed N/A from the prior year.
- Current Deferred Tax Assets eased to $41.2 million in Q2 2023 per APLM's latest filing, from $43.4 million in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $43.4 million in Q4 2022 and bottomed at $41.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Apollomics | 35.18 Mn | 31.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.87 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Jun 30, 2023 | 41.24 Mn |
| Jun 30, 2023 | 41.24 Mn |
| Dec 31, 2022 | 43.43 Mn |
| Dec 31, 2022 | 43.43 Mn |